Actionable news
All posts from Actionable news
Actionable news in ZGNX: Zogenix, Inc.,

Zogenix to have Significant Presence at 12th European Congress on Epileptology

EMERYVILLE, Calif., Sept. 08, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that the Company is sponsoring four poster presentations at the 12th European Congress on Epileptology (ECE), taking place this week in Prague, Czech Republic. One poster will feature an update on the efficacy and safety data on ZX008 (low-dose fenfluramine) as an adjunctive therapy for seizures associated with Dravet syndrome from the new patient cohort included in the ongoing Belgian open-label study. This poster will primarily be an encore of the data that were presented in a podium presentation at the 14th International Child Neurology Congress in May 2016.

The three burden of illness-related poster presentations will focus on better understanding the burden Dravet syndrome causes for the patient and their family, and also on identifying clinically relevant outcome measures to assess the impact on the lives of Dravet syndrome patients and their caregivers.

Once the last poster is presented, all four posters will be available here:

“Our presence at ECE, and our collaborative research into the disease burden of Dravet syndrome, is indicative of Zogenix’s commitment to patients and their families affected by epilepsy,” said Stephen J. Farr, Ph.D., President and CEO. “Importantly, we remain encouraged by the continued meaningful reduction in seizure frequency and sustained cardiovascular safety being demonstrated in the ongoing Belgian open-label study. We are also dedicated to identifying the core clinically relevant quality of life-related outcome measures associated with this devastating condition to better reflect the impact treatments may have. In addition, our ZX008 Phase 3 program for Dravet syndrome continues to enroll patients in the U.S. and internationally, and...